INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases. The Company is developing a new concept of immunomodulation targeting the amplification loops of the innate immune response with an initial focus on septic shock. With a high mortality rate, a growing incidence and a lack of specific mechanistically targeted treatment, severe sepsis and septic shock is a major public health problem in urgent need of a solution.

The INOTREM scientists and co-founders are international leaders in TREM-1 biology (Triggering Receptor Expressed on Myeloid cells-1) and authors of numerous studies demonstrating the role of TREM-1 in severe sepsis as well as myocardial infarction.

LASTEST publications

2018-01-18 - Martin Koch joins Inotrem as Chief Operating Officer   french or english

2017-09-11 - Inotrem announces new preclinical data supporting its lead compound’s (LR12) positive role on vascular dysfunction during septic shock   french or english

2016-09-13 - Inotrem successfully completes its first phase I clinical trial with Motrem, a TREM-1 pathway modulator for the treatment of septic shock 

See all publications